A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Primary Biliary Cholangitis Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03742973
• Other study ID #: 17039
• Secondary ID: I4V-MC-JAIV
• Status: Terminated
• Phase: Phase 2
• Start date: March 28, 2019
• Est. completion date: September 26, 2019

Study information

• Verified date: October 2019
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: September 26, 2019
• Est. primary completion date: September 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have a diagnosis of PBC (consistent with American Association for the Study of Liver Disease (AASLD) and European Association for Study of the Liver (EASL) Practice Guidelines; as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:

• History of elevated Alkaline Phosphatase (ALP) levels for at least 6 months

• Positive antimitochondrial antibodies titer

• Liver biopsy consistent with PBC

• Have ALP =1.67 x ULN but =6 x Upper Limit Normal (ULN).

• Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Week 0, or have previously taken, but are intolerant (in the opinion of the investigator) to UDCA and have not received UDCA for at least 12 weeks prior to Week 0.

• Nonpregnant, nonbreastfeeding female participants of childbearing potential.

Exclusion Criteria:

• History or presence of other concomitant liver diseases including:

• Hepatitis C virus (HCV) infection

• Hepatitis B virus (HBV) infection

• Primary sclerosing cholangitis

• Alcoholic liver disease

• Autoimmune liver disease other than PBC, such as overlap hepatitis

• Nonalcoholic steatohepatitis

• Gilbert's syndrome

• Presence of clinical complications of PBC or clinically significant hepatic decompensation, including:

• Liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score =15

• Portal hypertension with complications, including known gastric or esophageal varices, ascites, history of variceal bleeds or related therapeutic or prophylactic interventions (e.g., beta blockers, insertion of variceal bands or transjugular intrahepatic portosystemic shunt), or hepatic encephalopathy

• Cirrhosis, including history or presence of one or more of the following:

• spontaneous bacterial peritonitis

• hepatocellular carcinoma

• Hepatorenal syndrome (type I or II)

• Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of <90 milliliters/minute/1.73 m2.

• Have screening electrocardiogram (ECG) abnormalities that in the opinion of the investigator or the sponsor are clinically significant and indicate an unacceptable risk for the participant's participation in the study.

• Have experienced any of the following within 12 weeks of screening: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.

• Have a history of venous thromboembolism (VTE) (deep vein thrombosis/pulmonary embolism [DVT/PE]).

• Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.

• Have a current or recent (<4 weeks prior to randomization) clinically serious infection or any other active or recent infection that, in the opinion of the investigator, would pose an unacceptable risk to the participant if participating in the study.

• Have had symptomatic herpes zoster infection within 12 weeks prior to randomization.

• Have active tuberculosis (TB) disease determined on the basis of a positive medical history, physical examination, or chest radiography (per local standard of care) or latent TB infection (LTBI).

• Have any of the following specific abnormalities based on screening central lab test results:

• Hemoglobin <10 grams per deciliter (100.0 grams per liter)

• Alanine aminotransferase (ALT) >3 x ULN

• aspartate aminotransferase (AST) >3 x ULN

• alkaline phosphatase (ALP) >6 x ULN

• Total bilirubin level (TBL) >ULN

• Creatine phosphokinase (CPK) > ULN

• Serum albumin < lower limit of normal (LLN)

• International Normalized Ratio of Prothrombin Time (INR) > ULN

• Total white blood cell (WBC) count <LLN

• Absolute neutrophil count (ANC) <LLN

• Lymphocyte count <LLN

• Platelet (thrombocyte) count <LLN

• Are receiving unstable treatment for pruritus within 6 weeks prior to Week 0.

• Have been treated with systemic (oral or parenteral) corticosteroids within 6 weeks prior to Week 0.

• Have received biologic treatments for an immunologic disease within 4 weeks of screening.

• Have received a Janus kinase (JAK) inhibitor.

• Have received obeticholic acid.

• Have received fenofibrate or other fibrates for the treatment of PBC.

Related Conditions & MeSH terms

• Cholangitis
• Liver Cirrhosis, Biliary
• Primary Biliary Cholangitis

Intervention

Drug:
• Baricitinib
Administered orally.
• Placebo
Administered orally.

Locations

Country	Name	City	State
Puerto Rico	Klinical Investigations Group, LLC	San Juan
Puerto Rico	University of Puerto Rico, Medical Sciences Campus	San Juan
United States	University of Colorado School of Medicine	Aurora	Colorado
United States	The Institute for Digestive Health and Liver Disease at Mercy	Baltimore	Maryland
United States	UH Cleveland Medical Center	Cleveland	Ohio
United States	Southern California GI and Liver Centers (SCLC)	Coronado	California
United States	Henry Ford Hospital	Detroit	Michigan
United States	Baylor College of Medicine	Houston	Texas
United States	Schiff Center for Liver Diseases/University of Miami	Miami	Florida
United States	NYU Langone	New York	New York
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	University of California, Davis - Health Systems	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Alkaline Phosphatase (ALP)	Change from baseline in Alkaline Phosphatase (ALP)	Baseline, Week 12
Secondary	Percentage of Participants With Alkaline Phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN	Percentage of participants with alkaline phosphatase (ALP) <1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.	Week 12
Secondary	Change From Baseline in Itch Numeric Rating Scale (NRS)	Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.	Baseline, Week 12
Secondary	Change From Baseline in Fatigue NRS	Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.	Baseline, Week 12

External Links

•   Click here for more information about this study: A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA